Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
30 April 2020updated 06 Oct 2020 9:45am

Remdesivir trial shows “clear cut“ evidence the drug can aid Covid-19 recovery

By Samuel Horti

A clinical trial has shown “clear-cut” evidence that the antiviral drug remdesivir can help patients recover quicker from Covid-19, the US’s top infectious disease expert has said.

The randomised controlled trial of more than 1,000 patients was shown to cut the number of days infected patients took to leave hospital by nearly a third. Those taking the drug recovered after an average of 11 days, compared with 15 for those given a placebo.

Dr Anthony Fauci, one of the leading officials in the US’s coronavirus taskforce, said the trial was “a very important proof of concept”, and that “it has proven… that a drug can block this virus”.

Previously, smaller trials of remdesivir had suggested the drug, initally developed to treat Ebola, did not have a significant impact on coronavirus.

 

Select and enter your email address Quick and essential guide to domestic and global politics from the New Statesman's politics team. A weekly newsletter helping you fit together the pieces of the global economic slowdown. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. The New Statesman’s weekly environment email on the politics, business and culture of the climate and nature crises - in your inbox every Thursday. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A newsletter showcasing the finest writing from the ideas section and the NS archive, covering political ideas, philosophy, criticism and intellectual history - sent every Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
  • Administration / Office
  • Arts and Culture
  • Board Member
  • Business / Corporate Services
  • Client / Customer Services
  • Communications
  • Construction, Works, Engineering
  • Education, Curriculum and Teaching
  • Environment, Conservation and NRM
  • Facility / Grounds Management and Maintenance
  • Finance Management
  • Health - Medical and Nursing Management
  • HR, Training and Organisational Development
  • Information and Communications Technology
  • Information Services, Statistics, Records, Archives
  • Infrastructure Management - Transport, Utilities
  • Legal Officers and Practitioners
  • Librarians and Library Management
  • Management
  • Marketing
  • OH&S, Risk Management
  • Operations Management
  • Planning, Policy, Strategy
  • Printing, Design, Publishing, Web
  • Projects, Programs and Advisors
  • Property, Assets and Fleet Management
  • Public Relations and Media
  • Purchasing and Procurement
  • Quality Management
  • Science and Technical Research and Development
  • Security and Law Enforcement
  • Service Delivery
  • Sport and Recreation
  • Travel, Accommodation, Tourism
  • Wellbeing, Community / Social Services
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy